Laekna, Inc. (HKG:2105)

Market Cap	5.12B +44.9%
Revenue (ttm)	5.07M +604.3%
Net Income	-263.24M
EPS	-0.72
Shares Out	418.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,024,000
Average Volume	2,381,590
Open	12.18
Previous Close	12.23
Day's Range	12.18 - 12.94
52-Week Range	8.10 - 23.50
Beta	-1.08
RSI	41.22
Earnings Date	Mar 24, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 84
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2105

Financial Performance

In 2024, Laekna's revenue was 524,000, an increase of 11.49% compared to the previous year's 470,000. Losses were -254.30 million, -31.05% less than in 2023.

Financial numbers in CNY